Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Lin, Eliane Q ^a,b   Irvine, Jennifer C ^a   Cao, Anh H ^a,b   Alexander, Amy E ^a   Love, Jane E ^a   Patel, Ruchi ^a,b   McMullen, Julie R ^a   Kaye, David M ^a,b   Kemp Harper, Barbara K ^b   Ritchie, Rebecca H ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE I; ENDOTHELIN 1; GUANYLATE CYCLASE; KT 5823; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN BETA; NITRIC OXIDE DONOR; NITROXYL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SODIUM TRIOXODINITRATE; SOLUBLE GUANYLYL CYCLASE; SUPEROXIDE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; CELL ADHESION MOLECULE; CELL RECEPTOR; NITRITE; NITROGEN OXIDE; OXYHYPONITRITE; PHOSPHOPROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART HYPERTROPHY; HEART MUSCLE CELL; HORMONE INHIBITION; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; ANIMAL; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

RATTUS;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CELL ADHESION MOLECULES; CYCLIC GMP; ENDOTHELIN-1; GUANYLATE CYCLASE; MICROFILAMENT PROTEINS; MYOCYTES, CARDIAC; NADPH OXIDASE; NATRIURETIC PEPTIDE, BRAIN; NITRITES; NITROGEN OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; SUPEROXIDES;

EID: 84859608330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034892     Document Type: Article

References (50)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP, (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566.
2. Bernardo BC, Weeks KL, Pretorius L, McMullen JR, (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther128: 191-227.
3. Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, et al. (2009) Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond. Pharmacol Ther 124: 279-300.
4. Dunn FG, McLenachan J, Isles CG, Brown I, Dargie HJ, et al. (1990) Left ventricular hypertrophy and mortality in hypertension- an analysis of data from the Glasgow Blood Pressure Clinic. J Hypertens 8: 775-782.
5. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G, (2004) Adaptive and maladaptive hypertrophic pathways: Points of convergence and divergence. Cardiovasc Res 63: 373-380.
6. Irvine JC, Favaloro JL, Kemp-Harper BK, (2003) NO- activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 41: 1301-1307.
7. Favaloro JL, Kemp-Harper BK, (2007) The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc Res 73: 587-596.
8. Paolocci N, Katori T, Champion HC, St John ME, Miranda KM, et al. (2003) Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: Independence from β-adrenergic signaling. Proc Natl Acad Sci USA 100: 5537-5542.
9. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, et al. (2001) Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA 98: 10463-10468.
10. Cheong E, Tumbev V, Abramson J, Salama G, Stoyanovsky DA, (2005) Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium 37: 87-96.
11. Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, et al. (2007) Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res 100: 96-104.
12. Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, et al. (2008) Nitroxyl (HNO): The Cinderella of the nitric oxide story. Trends Pharmacol Sci 29: 601-608.
13. Bullen ML, Miller AA, Andrews KL, Irvine JC, Ritchie RH, et al. (2011) Nitroxyl (HNO) as a vasoprotective signaling molecule. Antiox Redox Signal 14: 1675-1686.
14. Miranda KM, Yamada K, Espey MG, Thomas DD, DeGraff W, et al. (2002) Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys 401: 134-144.
15. Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK, (2007) Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 49: 885-892.
16. Maragos CM, Morley D, Wink DA, Dunams TM, Saavedra JE, et al. (1991) Complexes of •NO with nucleophiles as agents for the controlled biological release of nitric oxide. vasorelaxant effects. J Med Chem 34: 3242-3247.
17. Li CG, Karagiannis J, Rand MJ, (1999) Comparison of the redox forms of nitrogen monoxide with the nitrergic transmitter in the rat anococcygeus muscle. Br J Pharmacol 127: 826-834.
18. Wink DA, Cook JA, Pacelli R, DeGraff W, Gamson J, et al. (1996) The effect of various nitric oxide-donor agents on hydrogen peroxide-mediated toxicity: a direct correlation between nitric oxide formation and protection. Arch Biochem Biophys 331: 241-248.
19. Fukuto JM, Chiang K, Hszieh R, Wong PSY, Chaudhurri G, (1992) The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 263: 546-551.
20. Irvine JC, Kemp-Harper BK, Widdop RE, (2011) Chronic administration of the HNO donor, Angeli's salt does not lead to tolerance, cross-tolerance or endothelial dysfunction: Comparison with GTN and DEA/NO. Antiox Redox Signal 14: 1615-1624.
21. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, et al. (2006) Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72: 112-123.
22. Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, Schiebinger RJ, (1998) Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 31: 39-44.
23. Ritchie RH, Schiebinger RJ, Lapointe MC, Marsh JD, (1998) Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 275: H1370-H1374.
24. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH, (2003) B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart- importance of cyclic GMP. Diabetes 52: 2389-2395.
25. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH, (2002) Acute antihypertrophic actions of bradykinin in the rat heart- importance of cyclic GMP. Hypertension 40: 498-503.
26. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH, (2003) Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: Importance of cyclic GMP. Cardiovasc Res 57: 515-522.
27. Ritchie RH, Rosenkranz AC, Kaye DM, (2009) B-type natriuretic peptide: Endogenous regulator of myocardial structure, biomarker and therapeutic target. Curr Mol Med 9: 814-825.
28. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, et al. (2002) Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 99: 11363-11368.
29. Lopez BE, Shinyashiki M, Han TH, Fukuto JM, (2007) Antioxidant actions of nitroxyl (HNO). Free Rad Biol Med 42: 482-491.
30. Ritchie RH, Rosenkranz AC, Huynh LP, Stephenson T, Kaye DM, et al. (2004) Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling. Am J Physiol 287: H1179-H1185.
31. Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, et al. (2007) The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 42: 1119-1128.
32. Goh SSC, Woodman OL, Pepe S, Cao AH, Qin CX, et al. (2007) The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid Redox Signal 9: 101-113.
33. Mulsch A, Luckhoff A, Pohl U, Busse R, Bassenge E, (1989) LY-83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic-GMP increases and inhibition of platelet activation. Naunyn-Schmied Arch Pharmacol 340: 119-125.
34. Vleeming W, van de Kuil A, te Biesebeek JD, Meulenbelt J, Boink AB, (1997) Effect of nitrite on blood pressure in anaesthetized and free-moving rats. Food Chem Toxicol 35: 615-619.
35. Zeller A, Wenzl MV, Beretta M, Stessel H, Russwurm M, et al. (2009) Mechanisms underlying activation of soluble guanylate cyclase by the nitroxyl donor Angeli's salt. Mol Pharmacol 76: 1115-1122.
36. Sugden PH, Clerk A, (2006) Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antiox Redox Signal 8: 2111-2124.
37. Xu Q, Dalic A, Fang L, Kiriazis H, Ritchie RH, et al. (2011) Myocardial oxidative stress contributes to transgenic β2-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol 162: 1012-1028.
38. Matsui T, Nagoshi T, Rosenweig A, (2003) Akt and PI 3-Kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2: 220-223.
39. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, et al. (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19: 6341-6350.
40. Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, et al. (2007) Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 104: 14074-14079.
41. Ito H, Bell D, Tamamori M, Nozato T, Shimojo T, et al. (1997) Calcitonin gene-related peptide (CGRP) and hypertrophy of cardiomyocytes. Heart Vessels Suppl. 12: 15-17.
42. Supowit SC, Rao A, Bowers MC, Zhao H, Fink G, et al. (2005) Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension 45: 109-114.
43. Lancel S, Zhang J, Evangelista A, Trucillo MP, Tong X, et al. (2009) Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. Circ Res 104: 720-723.
44. Froehlich JP, Mahaney JE, Keceli G, Pavlos CM, Goldstein R, et al. (2008) Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry 47: 13150-13152.
45. Horowitz JD, (2003) Amelioration of nitrate tolerance: Matching strategies with mechanisms. J Am Coll Cardiol 41: 2001-2003.
46. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HHHW, et al. (2006) NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nature Rev Drug Discov 5: 755-768.
47. Miller TW, Cherney MM, Lee AJ, Francoleon NE, Farmer PJ, et al. (2009) The effects of nitroxyl (HNO) on soluble guanylate cyclase activity. J Biol Chem 284: 21788-21796.
48. Tocchetti CG, Stanley BA, Murray CI, Sivakumaran V, Donzelli S, et al. (2011) Playing with Cardiac "Redox Switches": The "HNO Way" to Modulate Cardiac Function. Antioxid Redox Signal 14: 1687-1698.
49. Asad Z, Craig HJ, Sabzali J, Karmazyn M, (2011) mTOR mediates RhoA-dependent leptin-induced cardiomyocyte hypertrophy. Mol Cell Biochem 352: 99-108.
50. Haeuselmann SP, Rosc-Schlueter BI, Lorenz V, Plaisance I, Brink M, et al. (2011) β1-Integrin is up-regulated via Rac1-dependent reactive oxygen species as part of the hypertrophic cardiomyocyte response. Free Rad Biol Med 51: 609-618.